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Abstract
Objectives—To develop RNA profiles that could serve as novel biomarkers for the response to 
aspirin.
Background—Aspirin reduces death and myocardial infarction (MI) suggesting that aspirin 
interacts with biological pathways that may underlie these events.
Methods—We administered aspirin, followed by whole blood RNA microarray profiling, in a 
discovery cohort of healthy volunteers (HV1,n=50), and two validation cohorts of volunteers 
(HV2,n=53) or outpatient cardiology patients (OPC, n=25). Platelet function was assessed by 
platelet function score (PFS; HV1/HV2) or VerifyNow Aspirin (OPC). Bayesian sparse factor 
analysis identified sets of coexpressed transcripts, which were examined for association with PFS 
in HV1 and validated in HV2 and OPC. Proteomic analysis confirmed the association of validated 
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transcripts in platelet proteins. Validated gene sets were tested for association with death/MI in 
two patient cohorts (n=587, total) from RNA samples collected at cardiac catheterization.
Results—A set of 60 co-expressed genes named the “aspirin response signature” (ARS) was 
associated with PFS in HV1 (r = −0.31, p = 0.03), HV2 (r = −0.34, Bonferroni p = 0.03), and OPC 
(p = 0.046). Corresponding proteins for 17 ARS genes were identified in the platelet proteome, of 
which, six were associated with PFS. The ARS was associated with death/MI in both patient 
cohorts (odds ratio = 1.2, p = 0.01 and hazard ratio = 1.5, p = 0.001), independent of 
cardiovascular risk factors. Compared with traditional risk factors, reclassification (net 
reclassification index = 31 - 37%, p ≤ 0.0002) was improved by including the ARS or one of its 
genes, ITGA2B.
Conclusions—RNA profiles of platelet-specific genes are novel biomarkers for identifying 
those do not response adequately to aspirin and who are at risk for death/MI.
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Introduction
Identification of novel biomarkers for individuals at risk for CAD mortality, primarily due to 
platelet-mediated cardiovascular events such as MI, is a priority for reducing the burden of 
cardiovascular disease. Although genome-wide surveys of genomic variation and gene 
expression can identify loci associated with CAD (1-3), few can serve as biomarkers for 
cardiovascular events(4).
Aspirin is prescribed for the prevention of cardiovascular events, suggesting that aspirin 
interacts with biological pathways that may underlie these events. Platelet function assays 
are a surrogate biomarker for the effects of aspirin and are associated with cardiovascular 
events.(5) However, platelet function testing is not widely available primarily due to 
technical complexity. In contrast, whole blood RNA profiling using PCR-based assays is 
currently a widely available diagnostic testing platform. (6,7) Therefore, we hypothesized 
that aspirin could be used as a probe in conjunction with whole blood RNA profiling to 
elucidate novel biomarkers for platelet function in response to aspirin and for cardiovascular 
outcomes.
Methods
Platelet Function Outcomes in Healthy Volunteers Cohorts at Duke University Medical 
Center (DUMC)
We previously described (8) discovery and validation healthy volunteer cohorts (HV1 and 
HV2, Supplemental Methods, Figure 1) and the platelet function score (PFS) - a composite 
metric of the following platelet function assays: PFA100 (collagen/epinephrine) closure time 
and the areas under the optical aggregometry curve induced by adenosine diphosphate (10, 
5, 1uM), epinephrine (10, 1, 0,5 uM), and collagen (5, 2 mg/ml). We measured the PFS and 
mean platelet volume (MPV) in HV1 (n = 50) after 2 weeks of dosing with 325 mg/day non-
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enteric coated, immediate release aspirin and HV2 (n = 53) after 4 weeks of dosing with 325 
mg/day aspirin. In both cohorts whole blood RNA was collected into PAXgene® Blood 
RNA tubes (Becton, Dickinson, NJ, USA) before after aspirin exposure and stored at −80 C 
until microarray profiling. Platelet count was measured in platelet rich plasma in HV1.
Because three subjects in HV2 had participated in HV1, these were dropped from HV2, 
leaving 50 unique HV2 subjects. DUMC IRB approved the study protocols.
Platelet Function Outcomes in Patients At Risk For Cardiovascular Events At George 
Washington University (GWU)
We previously described (9) an outpatient cardiology cohort (OPC, Supplemental Methods, 
Figure 1) treated with 81mg/day aspirin assessed with the VerifyNow Aspirin device and 
whole blood RNA microarray analysis.
Clinical Outcomes in DUMC Patients
CATHGEN biorepository—The Catheterization Genetics (CATHGEN) biorepository has 
banked, whole blood RNA in PAXgene® tubes from DUMC patients from the time of 
cardiac catheterization, baseline medical history, and follow up for all-cause death and MI.
(10,11) Two cohorts had available microarray data (Supplemental Methods, Figure 2):
Observational cohort: 224 sequential samples were selected for RNA analysis, of which, 
191 had sufficient RNA for microarray analysis.
Case:control cohort: A nested case:control cohort of participants who had experienced 
death or MI (n = 250) after their index catheterization and age-, sex-, and race-matched 
controls (n = 250) who were free of death/MI > 2 years after cardiac catheterization was 
identified.(12) 447 had sufficient RNA for microarray analysis; 44 overlapped with the 
observational cohort and were dropped, leaving 403 subjects for analysis.
Follow-up for death/MI was ascertained in both cohorts in October 2011; the median follow-
up was 3.8 years. Patients with incomplete follow-up were censored at the time of last 
contact. Patients who had a history of cardiac transplantation at the time of catheterization (n 
=5), died within seven days (n =1), or failed quality control (n =1) were excluded. The 
remaining datasets left 190 samples in the observational cohort (48 death/MI events) and 
397 (202 death/MI events) in the case-control cohort.
RNA extraction, labeling, microarray hybridization, quality control, and normalization
See Supplementary Methods for full details. Two microarray platforms were utilized: 
Affymetrix U133A2 array (HV-1, pre-aspirin) and U133 plus 2.0 array (all others). The 
Robust Multichip Average (RMA) method was used for normalization.
Real-Time PCR
See Supplementary Methods. Forty-five transcripts were selected for verification in the 
original RNA samples based on two criteria: 1) the strength of correlation of the probe set 
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with PFS and 2) the strength of membership between the probe set and the set of co-
expressed genes of interest.
Platelet purification, Protein Sample Preparation, and Proteomics Analysis by LC-MS/MS
See Supplemental Methods.
Statistical Analysis
The raw and normalized microarray data are available in the Gene Expression Omnibus for 
the OPC cohort (GSE38511). The data for the HV1, HV2, and CATHGEN cohorts is 
available through the database of Genotypes and Phenotypes (phs000548.v1.p1 and 
phs000551.v1.p1). Unless stated otherwise, all tests were two-sided and were performed in 
R (2.10.0) or Matlab (R2010b); a p-value of < 0.05 was considered significant.
Discovery of coexpressed gene sets associated with PFS - Factor Modeling—
The HV1, post-aspirin RMA normalized data were nonspecifically filtered (i.e., without 
regard to PFS) to remove probes with mean expression less than 2.0 (i.e., the gene was not 
expressed in whole blood) or with variance less than 0.25 (i.e., the gene was homogenously 
expressed), resulting in 2,929 probe sets for subsequent analysis. To discover “Factors” or 
sets of coexpressed genes representative of biological pathways, we used Bayesian factor 
regression modeling (BFRM, http://www.isds.duke.edu/research/software/west/bfrm/)
(13,14) in an unsupervised fashion (i.e., without regard to PFS). Each of the probe sets used 
to estimate a particular Factor can be interpreted as a measurement of the activity of some 
(potentially unknown) biological pathway. Each sample can then be assigned a “Factor 
score”, which represents the aggregate expression of the transcripts within a Factor. The 
Factor scores can then be used for association with the phenotype of interest in subsequent 
analyses.
Factor projection, Gene membership within a Factor, Comparison of factor 
gene lists with selected gene sets, and Co-expression of transcripts 
represented by a Factor before and after aspirin exposure—See Supplemental 
Methods
Correlations between factor scores and platelet function—Pearson correlation 
was used to test for association between a Factor and PFS in HV1 and HV2. In the second 
validation cohort, OPC, we chose a one-sided t-test because we hypothesized a lower factor 
score in the aspirin-resistant vs. aspirin-sensitive groups.
Linear regression was used to assess the independent association of Factor scores and PFS 
after accounting for log-transformed MPV and/or platelet count.
Correction for multiple hypotheses testing—As HV1 was a hypothesis-generating 
pilot study we did not adjust p-values. In the first validation cohort, HV2, we adjusted p-
values using Bonferonni correction. In the second validation cohort, we performed only one 
hypothesis test.
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Analyses of RT-PCR data—The expression of each selected transcript relative to the 
three reference genes was expressed as Δ Cq (or “deltaCq”, See Supplemental Methods) and 
correlated with the corresponding microarray probe set or platelet function score using 
Pearson tests of correlation.
Platelet proteomic dataset analysis—See Supplemental Methods.
Analyses of CATHGEN cohorts—Logistic or Cox proportional hazards regression 
models were created in the case:control or observational cohorts, respectively, to test for 
association between the Factor and death/MI. Each model tested the Factor alone as well as 
after controlling for baseline variables (Supplemental Data, Table 6) associated with the 
Factor of interest. The assumption of proportional hazards for each Cox model was met. 
Odds (or hazards) ratios, 95% confidence intervals, and p-values are reported.
To assess the independent association between the Factor and death/MI, logistic regression 
models were built on the combined CATHGEN cohorts by forcing Framingham risk factors 
(age, sex, smoking, diabetes, hypertension, hyperlipidemia), African-American [AA] race, 
cohort, platelet count, and the presence of CAD (defined as a CAD index(15) >32 or history 
of coronary artery bypass surgery/MI/percutaneous coronary intervention), into the model 
and adding the Factor score or individual probe set gene expression. To assess the 
incremental prognostic value of gene expression we compared the performance of 
competing models (risk factors ± Factor/probe set expression), using the areas under the 
receiver operating characteristics curve (ROC) (16), the net reclassification index (NRI, 
using risk categories of < 10%, 10-20%, or > 20%(17) or category-free NRI (18), and the 
integrated discrimination improvement [IDI] (17)).
Results
Discovery and validation of a set of co-expressed genes in whole blood that correlate with 
platelet function on aspirin
In the discovery cohort (HV1) we identified 20 Factors (numbered 1 - 20, Supplemental 
Data, Table 1) representing sets of highly correlated, co-expressed genes. To test the 
hypothesis that one or more of these gene sets were associated with PFS on aspirin, we 
correlated each set with PFS in HV1 and identified “Factor 14” (Figure 1A) and “Factor 3” 
(r = 0.27, p-value = 0.05). In the first validation cohort (HV2), we found a significant 
association between Factor 14 and PFS, with the same strength and direction as observed in 
HV1 (Figure 1B, Bonferroni adjusted p-value = 0.03), thus validating this association, 
however Factor 3 was not associated with PFS in HV2. We further validated Factor 14 with 
VerifyNow test results in the OPC cohort (Figure 2). Thus Factor 14, which we named the 
“aspirin response signature” (ARS), was validated in two independent cohorts as a set of co-
expressed genes associated with platelet function on aspirin.
To verify the microarray-based expression of the ARS transcripts, we selected 45 of the 60 
genes (see Methods for selection criteria) for verification in whole blood RNA from the 
HV2 cohort. Using RT-PCR, 42/45 transcripts significantly correlated with their microarray-
based expression with 16/42 transcripts, including ITGA2B, TREML1, MYL9, and MPL, 
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strongly (r > 0.80) correlating with microarray based gene expression (Figure 3 and 
Supplemental Data, Table 2). For the majority of transcripts there was concordance between 
both the RT-PCR and microarray correlations with PFS (Supplemental Data, Table 3 and 
Figure 1). Therefore, RT-PCR assays validate the microarray-based expression associations 
with PFS for most ARS transcripts.
Aspirin response signature transcripts are primarily of platelet origin
We observed that the transcripts with the strongest correlation with PFS (Table 1) mapped to 
several well-known platelet transcripts: ITGA2B, CLU, IGF2BP3, GP1BB, and SPARC. 
Based on this observation we hypothesized that transcripts represented by the ARS were of 
platelet origin. To test this hypothesis, we examined the overlap and enrichment of the 60 
genes represented by the ARS with pre-defined gene sets specific to various peripheral 
blood cell types. Up to 24 of the 60 ARS genes significantly overlapped with platelet- or 
megakaryocyte-specific genes, whereas none overlapped with non-platelet peripheral blood 
cell type genes (Supplemental Data, Tables 4 and 5). Further, in the CATHGEN cohorts, we 
found the strongest correlation between expression of the ARS and platelet count (r = 0.41, p 
< 2e−16) with no strong, positive correlations with any other peripheral blood cell type 
counts: white blood cells (r = −0.01, p = 0.87), lymphocytes (r = −0.25, p = 1.2e-05), 
neutrophils (r = 0.16, p = 0.01), or monocytes (r = 0.06, p = 0.27).
To confirm the platelet origin of the ARS genes, we analyzed purified platelet lysates by 
label-free proteomics in the HV2 cohort. We identified 17 proteins from the ARS gene set in 
the proteomics dataset, of which, six were associated with PFS including ITGA2B, ITGB3, 
and MYL9 (Table 2), all in the same direction their corresponding transcripts. Therefore, 
from these data we conclude that a large number of ARS transcripts originate in platelets 
and are thus reporting on a coexpressed pathway of platelet transcripts and proteins 
associated with platelet function on aspirin.
Because mean platelet volume (MPV) is associated with platelet function (19) and the 
platelet origin of ARS transcripts, we assessed the extent to which the association between 
ARS and PFS was confounded by platelet volume or count. After controlling for MPV, the 
ARS remained significantly (adjusted regression coefficient for ARS = −0.5, standard error 
= 0.2, and p-value = 0.05 for HV1; and −0.87, 0.4, and p-value = 0.03 for HV2) associated 
with PFS. Further, in HV1, where platelet count and volume were both measured, the ARS 
remained significantly (−0.5 ± 0.2, p = 0.04) associated with PFS after their inclusion. 
Therefore, the association between ARS and platelet function is independent of other readily 
available platelet parameters such as count and MPV.
Prior to the administration of aspirin, the aspirin response signature is not associated with 
platelet function
Because pre-aspirin platelet function is a strong predictor of post-aspirin platelet function(8), 
we tested the hypothesis that the aggregate expression of the ARS genes was correlated with 
native, pre-aspirin PFS. In neither HV1 nor HV2 did we observe a correlation between the 
ARS and pre-aspirin PFS (Figure 3). Despite the absence of a correlation with PFS prior to 
aspirin, the ARS genes were similarly co-expressed before and after aspirin exposure 
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(Supplemental Data, Figure 2). Therefore, although the set of ARS genes are highly 
correlated with one another prior to aspirin exposure, their aggregate expression does not 
appear to contribute to native, pre-aspirin platelet function. Instead, the expression of the 
ARS genes specifically reflects platelet function on aspirin.
The aspirin response signature is an independent prognostic biomarker for cardiovascular 
events
Because of the association of the ARS with platelet function on aspirin and aspirin’s role in 
preventing cardiovascular events, we tested the hypothesis that the ARS was associated with 
the risk of death/MI in two independent patient cohorts. In both case-control and 
observational cohorts, the ARS was significantly associated with death/MI in univariate 
analyses (odds ratio [OR] =1.2, 95% confidence interval [CI] =1.04-1.4, p =0.04 and hazard 
ratio [HR] =1.4, [CI] = 1.1-1.7, p =0.002, respectively). The majority of the individual 
transcripts represented by the ARS were also associated with death/MI in both cohorts. 
(Supplemental Data, Table 7)
To determine the extent to which the ARS or an individual probe set for ITGA2B was an 
independent prognostic biomarker for events, we combined the CATHGEN cohorts and 
found that the ARS (OR =1.3, CI = [1.1, 1.5], p =0.001) or the microarray-based expression 
of ITGA2B (probe set = 206494_s_at, OR = 1.5, CI = [1.2, 1.8], p = 0.0001) were 
independently associated with death/MI after adjustment for Framingham risk factors(20), 
race, platelet count, and presence of angiographic CAD.
To further assess the potential use of the ARS as a risk biomarker we tested the hypothesis 
that the ARS or ITGA2B probe set expression would improve measures of discrimination. 
Compared with a model using clinical risk factors alone, the inclusion of the ARS improved 
most measures of risk discrimination (Table 3, Figure 5A). Inclusion of ITGA2B probe set 
expression significantly improved all measures of discrimination (Table 3, Figure 5B). Thus, 
the ARS or the expression of an individual ARS transcript such as ITGA2B were 
independent prognostic biomarkers for risk of death/MI.
Discussion
We used aspirin as a probe to identify novel genes and biomarkers associated with platelet 
function and cardiovascular events. We hypothesized that administering aspirin while 
simultaneously assaying the blood transcriptome might identify sets of genes that are related 
to aspirin’s cardioprotective effect. We identified a set of platelet-enriched, co-expressed 
genes and proteins, the “ARS”, that was reproducibly associated with platelet function in 
response to aspirin. When tested as a prognostic biomarker, the ARS or an individual ARS 
transcript (e.g., ITGA2B), independently and incrementally predicted the risk of death/MI 
compared with traditional risk factors. Our data shows that 1) the genomic response to a 
pharmacologic “challenge” with aspirin can reveal genes that underlie platelet function on 
aspirin and mechanisms responsible for death/MI and 2) that whole blood RNA profiling 
may identify novel biomarkers that discriminate individuals at heightened risk for death/MI.
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Transcripts associated with platelet function on aspirin are associated with cardiovascular 
events
We found neither association between the ARS and the presence of CAD, nor overlap 
between ARS genes those previously associated with CAD.(1,6) Instead, we found that the 
ARS was associated with death/MI after controlling for CAD and CAD risk markers. These 
findings highlight a unique and novel role that the biologic pathway represented by ARS 
genes have in the development of cardiovascular events, independent of CAD. We conclude 
that the biology of aspirin is complex and involves additional mechanisms beyond inhibiting 
platelet COX-1 and some of these mechanisms underlie risk for cardiovascular events.
A novel and translatable biomarker of platelet function in response to aspirin and the risk 
for cardiovascular events
Clinicians currently need a readily available biomarker for the response to aspirin. Despite 
the availability of platelet function assays, their widespread use is severely constrained by 
the need for specialized equipment and trained personnel. Point-of-care tests are available, 
but require testing to be completed within hours of phlebotomy; thus, they are out of reach 
for the vast majority of outpatients on aspirin. Further, most patients taking aspirin for 
chronic prevention are outpatients where results at the point-of-care are not required. 
Instead, testing in central laboratories, as is common for LDLc for statins, would be 
sufficient for determining aspirin response in the outpatient setting. Because of the 
coexpressed nature of the ARS genes, several individual transcripts (Table 1) correlated best 
with platelet function. We demonstrated that PCR for individual transcripts could be used in 
lieu of microarrays (Figure 3 and Supplemental Data, Table 2) for many ARS genes, thus 
demonstrating the feasibility of a blood-based diagnostic test.
Whole blood RNA testing is a well-established testing diagnostic testing platform. For 
cardiac allograft rejection and CAD diagnosis, whole blood microarray analyses were both 
transitioned to a PCR-based platform(6,7): AlloMap® and Corus® CAD, respectively. 
AlloMap® has been approved by the FDA and both are covered by major insurances. 
Therefore, there is a feasible path for blood-based RNA biomarkers to clinical adoption, 
FDA approval and insurance coverage.
Peripheral blood gene expression profiling reveals co-expressed transcripts of platelet 
origin associated with platelet function in response to aspirin
The genes underlying variable platelet function on aspirin have been difficult to identify(21) 
or explain a small portion of the observed variability(22). We hypothesized that whole blood 
RNA profiling, which de facto contains platelet transcripts, would yield biological pathways 
important for the response to aspirin. We demonstrated that the transcripts represented by 
the ARS are likely of platelet origin (Supplemental Data, Tables 4 and 5). When we 
analyzed platelet-enriched protein, we not only confirmed the well-known roles of ITGA2B 
and ITGB3, but also and ascribe new roles many other platelet genes: MYL9, CLU, 
PPKAR2B, TREML1, and CTTN with respect to platelet function on aspirin and 
cardiovascular events. Additionally, recent genome wide association studies identified a 
PEAR1 polymorphism associated with platelet PEAR1 levels and platelet function on 
aspirin.(22) We excluded the probe set (228618_at) mapping to PEAR1 because its variance 
Voora et al. Page 8
J Am Coll Cardiol. Author manuscript; available in PMC 2014 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(0.21) fell below our variance criteria (0.25, see Methods). However, in a post hoc analysis, 
PEAR1 expression strongly correlated (r = 0.9) with ARS levels. Therefore, our approach 
identified previously known and novel platelet genes associated with platelet function in 
response to aspirin.
We observed an association between ARS and platelet function only after the administration 
of aspirin, suggesting that the latent effect of ARS genes on platelet function is unmasked in 
response to aspirin. Consistent with these findings, when we stratified the CATHGEN 
cohort by aspirin use, we observed that the association between the ARS and death/MI was 
higher in those using aspirin at the time of catheterization (OR = 1.4 vs. 1.1 in aspirin users 
vs. nonusers). We hypothesize that the molecular mechanisms represented by the ARS 
contributes minimally to native platelet function in the absence of aspirin. In contrast, when 
platelet COX-1, a protein not represented by the ARS, is suppressed by 325mg/day aspirin 
dosing(23), the effects of these platelet enriched genes is revealed such that the resulting 
level of platelet function is then determined by the ARS. Alternatively, aspirin exposure may 
alter the genomic and protein content of circulating platelets. The precise mechanism by 
which platelet function on aspirin is related to the expression of the ARS genes and proteins 
on aspirin is the subject of ongoing work.
Limitations
Several limitations deserve consideration. Neither platelet function nor mean platelet volume 
(MPV) were measured in CATHGEN. Therefore, we cannot know whether heightened ARS 
levels altered platelet function or volumes in addition to an increased risk of death/MI. To 
our knowledge, large cohorts with platelet function, banked RNA, longitudinal follow up, 
and a sufficient number of events are not available. Further, in our discovery and validation 
cohorts, the association of the ARS with PFS was independent of platelet count and MPV, 
suggesting the ARS provides an independent parameter of platelet function that underlies 
cardiovascular events. Second, although there was no association between the ARS and 
modifiable risk factors (e.g. diabetes, hyperlipidemia, or hypertension), because we did not 
assess the degree to which these risk factors were controlled we do not know if addressing 
these risk factors could modulate ARS levels. Finally, the comparison of the ARS gene set 
with that of platelets, megakaryocytes, and platelet proteomics analyses demonstrate that the 
top ARS genes correlative of platelet function on aspirin were of platelet origin. However, 
some ARS genes (e.g. TTC7B and FSTL1) are also expressed in non-platelet cell types, 
suggesting that mechanism(s) represented by ARS genes may involve more than just 
platelets.
Conclusion
In summary, we used aspirin as a probe in conjunction with RNA profiling and identified 
novel biomarkers that identify individuals at highest risk for death/MI independent of 
clinical risk factors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Voora et al. Page 9
J Am Coll Cardiol. Author manuscript; available in PMC 2014 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Acknowledgements
We would like to acknowledge Jason Rose, MD for collecting the platelet count data for the CATHGEN cohorts.
Funding: This study was funded by institutional funds provided by the Duke Institute for Genome Sciences & 
Policy, a National Institutes of Health (NIH) T32 Training grant (5T32HL007101 to DV), a grant 
(5UL1RR024128) from the National Center for Research Resources (NCRR), a component of the NIH, and NIH 
Roadmap for Medical Research, a grant (5RC1GM091083 to GSG) from the National Institutes of General Medical 
Sciences, grant (5U01DD000014 to TLO) from the Centers for Disease Control and Prevention, and the David H 
Murdock Research Institute.
Abbreviations
PFS Platelet Function Score
ARS Aspirin Response Signature
CAD Coronary Artery Disease
MI Myocardial Infarction
RT-PCR Real-time Polymerase Chain Reaction
PCR Polymerace Chain Reaction
RNA Ribonucleic Acid
IRB Institutional Review Board
DNA Deoxyribonucleic Acid
LDLc low density lipoprotein cholesterol
References
1. Wingrove JA, Daniels SE, Sehnert AJ, et al. Correlation of Peripheral-Blood Gene Expression With 
the Extent of Coronary Artery Stenosis. Circ Cardiovasc Genet. 2008; 1:31–38. [PubMed: 
20031539] 
2. Helgadottir A, Thorleifsson G, Manolescu A, et al. A Common Variant on Chromosome 9p21 
Affects the Risk of Myocardial Infarction. Science. 2007; 316:1491–1493. [PubMed: 17478679] 
3. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. 
N Engl J Med. 2007; 357:443–53. [PubMed: 17634449] 
4. Reilly MP, Li M, He J, et al. Identification of ADAMTS7 as a novel locus for coronary 
atherosclerosis and association of ABO with myocardial infarction in the presence of coronary 
atherosclerosis: two genome-wide association studies. Lancet. 2011; 377:383–92. [PubMed: 
21239051] 
5. Frelinger AL III, Li Y, Linden MD, et al. Association of Cyclooxygenase-1-Dependent and -
Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients 
Presenting for Cardiac Catheterization. Circulation. 2009; 120:2586–2596. [PubMed: 19996015] 
6. Rosenberg S, Elashoff MR, Beineke P, et al. Multicenter Validation of the Diagnostic Accuracy of a 
Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in 
Nondiabetic Patients. Annals of Internal Medicine. 2010; 153:425–434. [PubMed: 20921541] 
7. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-Expression Profiling for Rejection Surveillance 
after Cardiac Transplantation. New England Journal of Medicine. 2010; 362:1890–1900. [PubMed: 
20413602] 
8. Voora D, Ortel TL, Lucas JE, Chi JT, Becker RC, Ginsburg GS. Time-dependent changes in non-
COX-1-dependent platelet function with daily aspirin therapy. Journal of Thrombosis and 
Thrombolysis. 2012; 33:246–57. [PubMed: 22294277] 
Voora et al. Page 10
J Am Coll Cardiol. Author manuscript; available in PMC 2014 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
9. Fallahi P, Katz R, Toma I, et al. Aspirin insensitive thrombophilia: Transcript profiling of blood 
identifies platelet abnormalities and HLA restriction. Gene. 2013 Epub ahead of print. 
10. Wang L, Hauser ER, Shah SH, et al. Peakwide mapping on chromosome 3q13 identifies the kalirin 
gene as a novel candidate gene for coronary artery disease. American journal of human genetics. 
2007; 80:650–63. [PubMed: 17357071] 
11. Rosati RA, McNeer JF, Starmer CF, Mittler BS, Morris JJ Jr. Wallace AG. A New Information 
System for Medical Practice. Arch Intern Med. 1975; 135:1017–1024. [PubMed: 1156062] 
12. Shah SH, Granger CB, Hauser ER, et al. Reclassification of cardiovascular risk using integrated 
clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand 
the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 
Cardiovascular Disease Study. American Heart Journal. 2010; 160:371–379 e2. [PubMed: 
20826242] 
13. Wang Q, Carvalho C, Lucas JE, West M. BFRM: Bayesian factor regression modeling. Bulletin of 
the International Society of Bayesian Analysis. 2007; 14:4–5.
14. Carvalho CM, Chang J, Lucas JE, Nevins JR, Wang Q, West M. High-Dimensional Sparse Factor 
Modeling: Applications in Gene Expression Genomics. Journal of the American Statistical 
Association. 2008; 103:1438–1456. [PubMed: 21218139] 
15. Mark DB, Nelson CL, Califf RM, et al. Continuing evolution of therapy for coronary artery 
disease. Initial results from the era of coronary angioplasty. Circulation. 1994; 89:2015–25. 
[PubMed: 8181125] 
16. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated 
receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44:837–45. 
[PubMed: 3203132] 
17. Pencina MJ, D’Agostino RB Sr. D’Agostino RB Jr. Vasan RS. Evaluating the added predictive 
ability of a new marker: from area under the ROC curve to reclassification and beyond. Statistics 
in Medicine. 2008; 27:157–72. discussion 207-12. [PubMed: 17569110] 
18. Pencina MJ, D’Agostino RB Sr. Steyerberg EW. Extensions of net reclassification improvement 
calculations to measure usefulness of new biomarkers. Statistics in Medicine. 2011; 30:11–21. 
[PubMed: 21204120] 
19. Thompson CB, Eaton KA, Princiotta SM, Rushin CA, Valeri CR. Size dependent platelet 
subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. 
British Journal of Haematology. 1982; 50:509–19. [PubMed: 7066203] 
20. D’Agostino RB Sr. Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary 
heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA: the 
journal of the American Medical Association. 2001; 286:180–7.
21. Mathias R, Kim Y, Sung H, et al. A combined genome-wide linkage and association approach to 
find susceptibility loci for platelet function phenotypes in European American and African 
American families with coronary artery disease. BMC Medical Genomics. 2010; 3:22. [PubMed: 
20529293] 
22. Faraday N, Yanek LR, Yang XP, et al. Identification of a specific intronic PEAR1 gene variant 
associated with greater platelet aggregability and protein expression. Blood. 2011; 118:3367–
3375. [PubMed: 21791418] 
23. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet 
function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007; 
115:3156–64. [PubMed: 17562955] 
Voora et al. Page 11
J Am Coll Cardiol. Author manuscript; available in PMC 2014 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. The aggregate expression of a set of coexpressed, whole blood genes correlates with 
platelet function in response to aspirin
Two independent cohorts of healthy volunteers were exposed to 325mg/day aspirin, 
followed by whole blood microarray profiling. Platelet function was assessed by the platelet 
function score (PFS(8)). The aggregate expression of a set of coexpressed genes (aspirin 
response signature [ARS], x-axis), is plotted against the PFS (y-axis) after aspirin exposure. 
Pearson correlation coefficients and p-values are reported.
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Figure 2. Aspirin response signature (ARS) is associated with platelet function in patients at risk 
for cardiovascular disease
Patients treated with 81mg/day aspirin were assessed with the VerifyNow Aspirin device.(9) 
Three categories of individuals were profiled by microarray based on their aspirin response 
units (ARU): Aspirin resistant (AR, ARU > 550); High normal (HN, 500 < ARU < 550); 
Aspirin sensitive (AS, ARU < 550). ARS values are for each group are plotted and 
compared using two-sample t-tests. P-values are one-sided.
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Figure 3. PCR-based assays verify the microarray-based gene expression values for aspirin 
response signature genes
Real-time PCR assays were designed to verify selected transcripts represented by the aspirin 
response signature (ARS) in the HV2 cohort. The deltaCq for each assay was correlated with 
the RMA normalized, probe set expression for the corresponding ARS gene using Pearson 
correlation (see Supplementary Data, Table 2). For the four genes with the highest PCR vs. 
microarray-based correlation (ITGA2B, MYL9, TREML1, and MPL), we plot the relative 
quantity (2−deltaCq, x-axis, log-scale) vs. the corresponding probe set expression (y-axis), 
correlation coefficient, and p-value.
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Figure 4. A set of coexpressed peripheral blood genes does not correlate with native, pre-aspirin 
platelet function
The aggregate expression of coexpressed genes, is plotted against the platelet function 
before the administration of aspirin in the discovery cohort (HV1, A, n = 45) and validation 
cohort (HV2, B, n = 50) healthy volunteers. Pearson correlation coefficients and p-values 
are reported. ARS = aspirin response signature; PFS = platelet function score.
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Figure 5. Peripheral blood gene expression adds additional prognostic information for death or 
myocardial infarction
Patients in the case:control and observational cohorts were combined and analyzed with 
respect to death/myocardial infarction (MI) outcomes. The receiver operating characteristics 
curves were plotted for predictive models containing cardiovascular risk factors, platelet 
count, presence of coronary artery disease, cohort (collectively, CV) and gene expression, or 
both were compared. ARS = aspirin response signature. The probe set, 216956_s_at 
represents ITGA2B gene expression.
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Table 2
Aspirin response signature proteins identified in platelet protein and their correlations 
with PFS on aspirin
Protein Name Correlation with PFS p-value
TBB1 −0.32 0.02
GP1BB −0.29 0.03
ITA2B −0.29 0.03
ITB3 −0.28 0.04
MYL9 −0.27 0.05
RB27B −0.26 0.06
LEGL −0.24 0.08
TSP1 −0.24 0.08
CALD1 −0.22 0.11
SRC8 −0.21 0.12
SH3L2 −0.20 0.16
CXCL7 −0.20 0.15
SDPR −0.18 0.19
PLF4 −0.18 0.20
SPRC −0.14 0.31
PDE5A −0.09 0.49
CLUS 0.06 0.67
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Table 3
Measures of discrimination with and without inclusion of gene expression profiles
Measure Traditional
Risk
Factors
Traditional Risk
Factors
+ ARS
Traditional
Risk Factors
+
216956_s_at**
(ITGA2B)
Area under ROC curve
95% confidence interval [CI]
p-value*
0.72
[0.68-0.76]
n/a
0.73
[0.69-0.77]
0.3
0.74
[0.70-0.78]
0.04
Net reclassification index (<10%, 10-20%, >
20%)
CI
p-value
- 0.06
[0.02 – 0.10]
0.005
0.12
[0.07 - 0.17]
< 1e-05
Net reclassification index (category-free)
CI
p-value
- 0.31
[0.15 – 0.47]
2e-04
0.37
[0.21 – 0.54]
8.7e-06
Integrated discrimination improvement
CI
p-value
- 0.01
[0.002 – 0.02]
0.006
0.03
[0.02 – 0.05]
2e-05
*
all p-values are for comparisons with ‘Traditional Risk Factors’ model which includes: age, sex,African-American race, smoking, diabetes, 
hypertension, hyperlipidemia, cohort, and the presence of coronary artery disease;
**
The 216956_s_at probe set represents ITGA2B gene expression on the Affymetrix microarray; ARS = aspirin response signature; ROC = 
receiver operating characteristic
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